{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:33:25Z","timestamp":1722558805642},"reference-count":24,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The present study aimed to assess the bioequivalence of a new apixaban generic with reference formulation. Twenty\u2010six healthy volunteers were recruited for an open\u2010label, balanced, randomized, 2\u2010treatment, 2\u2010sequence, 2\u2010period, single oral dose study. Following overnight fasting, each volunteer received 5\u00a0mg of apixaban test and reference formulations as single doses, separated by a 1\u2010week washout period. Twenty blood samples were collected at predose and multiple time points between 0.5 and 72 hours after dosing. A validated ultra\u2010performance liquid chromatography\u2010tandem mass spectrometry detection method following a protein precipitation step was implemented to determine apixaban concentrations. Noncompartmental analysis was used to derive the pharmacokinetic parameters, which were then compared between the test and reference products using a multivariate analysis of variance. The pharmacokinetic parameters of the test product were not statistically different from the reference product, and the 90% confidence intervals of apixaban natural log\u2010transformed area under the concentration\u2010time curve from time 0 to infinity, area under the concentration\u2010time curve from time 0 to the last measurable concentration, and maximum concentration were within 80%\u2010125% based on the bioequivalence acceptance range criteria. The test and reference formulations of apixaban are bioequivalent in healthy subjects under fasting conditions.<\/jats:p>","DOI":"10.1002\/cpdd.1409","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T07:19:43Z","timestamp":1714461583000},"page":"890-896","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Apixaban Pharmacokinetics and Bioequivalence of Two Tablet Formulations: A Randomized, Open\u2010Label, Crossover Study, Fasting Condition in Healthy Indonesian Volunteers"],"prefix":"10.1002","volume":"13","author":[{"given":"Chuei Wuei","family":"Leong","sequence":"first","affiliation":[{"name":"Duopharma Innovation Sdn. Bhd.  Shah Alam Selangor Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kar Ming","family":"Yee","sequence":"additional","affiliation":[{"name":"Duopharma Innovation Sdn. Bhd.  Shah Alam Selangor Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Liew","sequence":"additional","affiliation":[{"name":"Duopharma Innovation Sdn. Bhd.  Shah Alam Selangor Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur Athirah","family":"Khaleb","sequence":"additional","affiliation":[{"name":"Duopharma Innovation Sdn. Bhd.  Shah Alam Selangor Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahnun","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Duopharma Innovation Sdn. Bhd.  Shah Alam Selangor Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy Ann","family":"Rani","sequence":"additional","affiliation":[{"name":"Duopharma Innovation Sdn. Bhd.  Shah Alam Selangor Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kheng Jim","family":"Lau","sequence":"additional","affiliation":[{"name":"Duopharma Innovation Sdn. Bhd.  Shah Alam Selangor Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danang Agung","family":"Yunaidi","sequence":"additional","affiliation":[{"name":"PT Equilab International  Jakarta Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronal","family":"Simanjuntak","sequence":"additional","affiliation":[{"name":"PT Equilab International  Jakarta Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky A.","family":"Ginanjar","sequence":"additional","affiliation":[{"name":"PT Equilab International  Jakarta Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm070245n"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S74410"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-011-0551-3"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780802528625"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-9560-11-27"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04369.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00775-z"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2013.07.009"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1309\/LMSXWC3A4LBIJP2B"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.023143"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.990"},{"issue":"4","key":"e_1_2_7_13_1","first-page":"206","article-title":"Role of apixaban (Eliquis) in the treatment and prevention of thromboembolic disease","volume":"38","author":"Budovich A","year":"2013","journal-title":"Pharm Ther"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH08-07-0486"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-35762-3.00149-9"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1097"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.05.004"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.628"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.029694"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.025981"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.964"},{"key":"e_1_2_7_22_1","unstructured":"European Medicines Agency.Assessment Report Apixaban Accord.2020. No. EMEA\/H\/C\/005358\/0000. Accessed October 28 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/apixaban\u2010accord"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e18422"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.05.497"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP204299"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T11:57:12Z","timestamp":1722513432000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1002\/cpdd.1409"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1409","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"type":"print","value":"2160-763X"},{"type":"electronic","value":"2160-7648"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"assertion":[{"value":"2024-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}